Bio-Rad Laboratories, Inc 8-K, filed May 1, 2020
Bio-Rad Laboratories, Inc. (BIO)
About this 8-K
Bio-Rad Laboratories, Inc filed this 8-K on May 1, 2020, reporting on events of April 28, 2020.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report:
(Date of earliest event reported)
(Exact name of registrant as specified in its charter)
Commission File Number:
| |
| |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| |
|
| ||
| |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| ITEM 5.07. | Submission of Matters to a Vote of Security Holders. |
Bio-Rad Laboratories, Inc. (the “Company”) held its Annual Meeting of Stockholders on April 28, 2020. The matters voted upon at the meeting and the results of those votes are set forth below.
1. Each of the nominated directors was elected and received the affirmative vote of a majority of the votes cast in the respective class of Common Stock, as follows:
| Class of |
||||||||||||||||||||
| Common Stock |
Votes |
Votes |
Votes |
Broker |
||||||||||||||||
| to Elect |
For |
Against |
Abstaining |
Non-Votes |
||||||||||||||||
| Melinda Litherland |
Class A |
17,962,956 |
667,378 |
11,017 |
2,418 |
|||||||||||||||
| Arnold A. Pinkston |
Class A |
18,162,789 |
467,253 |
11,309 |
2,418 |
|||||||||||||||
| Jeffrey L. Edwards |
Class B |
4,894,706 |
413 |
200 |
— |
|||||||||||||||
| Gregory K. Hinckley |
Class B |
4,894,706 |
413 |
200 |
— |
|||||||||||||||
| Alice N. Schwartz |
Class B |
4,892,763 |
2,556 |
— |
— |
|||||||||||||||
| Norman Schwartz |
Class B |
4,892,728 |
2,591 |
— |
— |
|||||||||||||||
2. The proposal to ratify the selection of KPMG LLP as the Company’s independent auditors for the fiscal year ending December 31, 2020 was ratified and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows:
| Votes For |
Votes Against |
Votes Abstaining |
Broker Non-Votes | |||||||
| 6,757,921 |
803 |
972 |
— | |||||||
3. The non-binding advisory vote to approve executive compensation was approved and received the affirmative vote of a majority of the voting power of the holders of Class A and Class B Common Stock, as follows:
| Votes For |
Votes Against |
Votes Abstaining |
Broker Non-Votes | |||||||
| 6,565,329 |
190,109 |
4,016 |
242 | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIO-RAD LABORATORIES, INC. | ||||||
| Date: May 1, 2020 |
By: |
/s/ Timothy S. Ernst | ||||
| Timothy S. Ernst | ||||||
| Executive Vice President, General Counsel and Secretary | ||||||